Datavant
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Founded Year
2017Stage
Series B | AliveTotal Raised
$80.5MLast Raised
$40M | 2 yrs agoAbout Datavant
Datavant is dedicated to accelerating the discovery, development, and commercialization of new medicines through machine learning. It aims to partner with biomedical research institutions to eliminate silos of information and unlock insights from healthcare data.
Datavant Headquarter Location
2 Embarcadero Center 7th Floor
San Francisco, California, 94111,
United States
+1 415 525 1171
ESPs containing Datavant
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Companies in this market offer alternative datasets that can supplement clinical trial data and improve the likelihood of trial success. These companies collect data from a variety of sources, such as patient registries, EHRs, insurance databases, social media, and patient research networks.
Datavant named as Leader among 15 other companies, including Syapse, Evidation, and Aetion.
Research containing Datavant
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Datavant in 3 CB Insights research briefs, most recently on Feb 2, 2022.
Expert Collections containing Datavant
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Datavant is included in 7 Expert Collections, including Clinical Trials Tech.
Clinical Trials Tech
329 items
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
Artificial Intelligence
9,093 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Conference Exhibitors
5,302 items
Digital Health
13,084 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Clinical Trials Tech Market Map
108 items
This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.
Biopharma Tech
1,164 items
Datavant Patents
Datavant has filed 6 patents.
The 3 most popular patent topics include:
- Data management
- Cryptography
- Information privacy
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/14/2019 | 9/21/2021 | Key management, Cryptography, Data management, Information privacy, Privacy | Grant |
Application Date | 11/14/2019 |
|---|---|
Grant Date | 9/21/2021 |
Title | |
Related Topics | Key management, Cryptography, Data management, Information privacy, Privacy |
Status | Grant |
Latest Datavant News
Aug 4, 2022
San Francisco, California, UNITED STATES VersaiSM , a Havas Health & You solution, Creates privacy protected 360-degree View of Patient and Provider Journeys Powered by Connected Medical and Consumer Data Sets NEW YORK and SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Datavant, the leader in helping organizations securely connect health data, has partnered with Havas Health & You (HH&Y), the world's largest global health network – specializing in communications, education, and innovation – to power Versai’s patient and healthcare provider advanced intelligence engine. Versai enables HH&Y health and wellness clients to identify, predict, and respond to patients and providers with confidence and speed. Versai’s advanced intelligence engine combines de-identified medical and consumer data, AI, technology and content to deliver personalized, omni-channel experiences that meet patient and healthcare provider (HCP) needs. Datavant will power Versai’s privacy and HIPAA compliant data connectivity with de-identified patient level matching, enabling the linkage of client 1st party data, 2nd and 3rd party data, survey data and engagement data. “Engaging patients and physicians in health decisions starts with data that helps you understand their personal health experiences and needs,” said Pat Thistlethwaite, Chief Experience Officer at HH&Y. “Versai will enable clients to complete the picture of patients’ health and its impact on their lives, and engage health providers with personalized experiences to build stronger relationships with their brands.” These rich, integrated patient datasets will support health and life sciences clients with multi-layered real world patient journey maps, comprehensive patient profiles, and predictive health intelligence for high precision targeting and engagement. Versai will provide similar insights about health professionals, enabling clients to understand each provider’s behavior as practitioners, their patient population, and their values as people. Together, these insights will help Versai create and orchestrate meaningful experiences that solve patients’ and providers’ problems in real time. “We are excited to partner with HH&Y to enable connectivity of patient and consumer data in a privacy protected manner,” noted Travis May, Founder and President of Datavant. “There is a need to have a fuller understanding of the factors that influence a person’s health which allows for better, data-backed decisions regarding patient care. The partnership between Datavant and HH&Y enables a richer view of patient journeys while protecting individual patient privacy.” About Datavant Datavant’s mission is to connect the world’s health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of patient health records across datasets. Learn more about Datavant at www.datavant.com . About Havas Health & You Havas Health & You unites Havas Life, Health4Brands (H4B), Lynx, Havas Life PR and Havas Health Plus, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Group. Its customer-centric approach has the talent, tenacity and technology that health-and-wellness companies, brands and people need to thrive in today’s world. Media Contacts:
Datavant Web Traffic
Datavant Rank
When was Datavant founded?
Datavant was founded in 2017.
Where is Datavant's headquarters?
Datavant's headquarters is located at 2 Embarcadero Center, San Francisco.
What is Datavant's latest funding round?
Datavant's latest funding round is Series B.
How much did Datavant raise?
Datavant raised a total of $80.5M.
Who are the investors of Datavant?
Investors of Datavant include Roivant Sciences, Transformation Capital, Johnson & Johnson Innovation, Cigna Ventures, Flex Capital and 5 more.
Who are Datavant's competitors?
Competitors of Datavant include Syapse, Owkin, Mendel.ai, ConcertAI, AllStripes, Verana Health, Holmusk, HealthVerity, Verantos, Aetion and 12 more.
You May Also Like
Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology.
Evidation measures health in everyday life and enables anyone to participate in research and health programs. Evidation is a two-sided platform that connects individuals and enterprises. On the consumer side, the company assists individuals to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.
Aetion delivers real-world evidence for life sciences companies, payers, at-risk providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce rapid and scientifically validated answers on treatments, costs, and outcomes. Aetion informs health care's most critical decisions - what works best, for whom, and when - to guide treatment development, commercialization, and payment values into health care's modern era.
ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.
Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations. The company was formerly known as BDLicense. Syapse was founded in 2008 and is based in San Francisco, California.
Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.